Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
2.100
-0.060 (-2.78%)
At close: Apr 28, 2026, 4:00 PM EDT
2.090
-0.010 (-0.48%)
After-hours: Apr 28, 2026, 7:59 PM EDT
Grace Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
32.50M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 8.96M |
| Evaxion | 7.53M |
| CervoMed | 4.01M |
| Dyadic International | 3.09M |
| Pluri | 1.34M |
| IGC Pharma | 1.11M |
| Daré Bioscience | 1.03M |
| Outlook Therapeutics | 205.70K |
GRCE News
- 4 days ago - Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug - Benzinga
- 5 days ago - US FDA declines to approve Grace Therapeutics' drug for a type of stroke - Reuters
- 5 days ago - Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104 - GlobeNewsWire
- 14 days ago - Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026 - GlobeNewsWire
- 5 weeks ago - Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences - GlobeNewsWire
- 7 weeks ago - Grace Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update - GlobeNewsWire